Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Short term Debt (2018 - 2025)

Ptc Therapeutics (PTCT) has 11 years of Short term Debt data on record, last reported at $286.6 million in Q4 2025.

  • For Q4 2025, Short term Debt rose 11.17% year-over-year to $286.6 million; the TTM value through Dec 2025 reached $286.6 million, up 11.17%, while the annual FY2025 figure was $286.6 million, 11.17% up from the prior year.
  • Short term Debt reached $286.6 million in Q4 2025 per PTCT's latest filing, roughly flat from $286.3 million in the prior quarter.
  • Across five years, Short term Debt topped out at $286.6 million in Q4 2025 and bottomed at $33.1 million in Q1 2021.
  • Average Short term Debt over 5 years is $157.2 million, with a median of $127.9 million recorded in 2022.
  • Peak YoY movement for Short term Debt: skyrocketed 238.13% in 2022, then fell 29.72% in 2023.
  • A 5-year view of Short term Debt shows it stood at $59.3 million in 2021, then increased by 21.69% to $72.1 million in 2022, then surged by 169.32% to $194.3 million in 2023, then skyrocketed by 32.68% to $257.8 million in 2024, then rose by 11.17% to $286.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Short term Debt were $286.6 million in Q4 2025, $286.3 million in Q3 2025, and $262.0 million in Q2 2025.